Literature DB >> 10665655

G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.

T Akiyama1, K Sugiyama, M Shimizu, T Tamaoki, S Akinaga.   

Abstract

7-Hydroxystaurosporine (UCN-01), which was originally identified as a protein kinase C selective inhibitor, is currently in clinical trials as an anti-cancer drug. We previously showed that UCN-01 induced preferential G1-phase accumulation in tumor cells and this effect was associated with the retinoblastoma (Rb) protein and its regulatory factors, such as cyclin-dependent kinase 2 (CDK2) and CDK inhibitors p21Cip1/WAF1 and p27Kip1. We demonstrate here that G1-phase accumulation was induced by UCN-01 in Rb-proficient cell lines (WiDr and HCT116 human colon carcinomas and WI-38 human lung fibroblast), and it was accompanied by dephosphorylation of Rb. In addition, UCN-01-induced G1-phase accumulation was also demonstrated in a Rb-defective cell line (Saos-2 human osteosarcoma), but not in a simian virus 40 (SV40)-transformed cell line (WI-38 VA13). Apoptosis was induced by UCN-01 in the two Rb-deficient cell lines, but not in the other Rb-proficient cell lines. These observations suggest that G1-checkpoint function might be important for cell survival during UCN-01 treatment. In addition, there may be a UCN-01-responsive factor in the G1-checkpoint machinery other than Rb which is targeted by SV40. Further studies revealed a correlation between UCN-01-induced G1-phase accumulation and reduction of cellular CDK2 kinase activity. This reduction was strictly dependent on down-regulation of the Thr160-phosphorylated form of CDK2 protein, and coincided in part with up-regulation of p27Kip1, but it was independent of the level of the p21Cip1/WAF1 protein. These results suggest that G1-checkpoint function, including a CDK2-regulatory pathway, may be a significant determinant of the sensitivity of tumor cells to UCN-01.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10665655      PMCID: PMC5926038          DOI: 10.1111/j.1349-7006.1999.tb00721.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  38 in total

Review 1.  Caspases and caspase inhibitors.

Authors:  P Villa; S H Kaufmann; W C Earnshaw
Journal:  Trends Biochem Sci       Date:  1997-10       Impact factor: 13.807

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  C-terminal truncation of the retinoblastoma gene product leads to functional inactivation.

Authors:  J Y Shew; B T Lin; P L Chen; B Y Tseng; T L Yang-Feng; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 4.  The transforming activity of simian virus 40 large tumor antigen.

Authors:  J J Manfredi; C Prives
Journal:  Biochim Biophys Acta       Date:  1994-05-27

5.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

Review 6.  Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.

Authors:  T K MacLachlan; N Sang; A Giordano
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1995       Impact factor: 1.807

7.  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Authors:  E Fuse; H Tanii; N Kurata; H Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; D Headlee; W D Figg; S G Arbuck; A M Senderowicz; E A Sausville; S Akinaga; T Kuwabara; S Kobayashi
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

Review 8.  Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators.

Authors:  B W Stewart
Journal:  J Natl Cancer Inst       Date:  1994-09-07       Impact factor: 13.506

9.  Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.

Authors:  O Aprelikova; Y Xiong; E T Liu
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

10.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.

Authors:  I Takahashi; Y Saitoh; M Yoshida; H Sano; H Nakano; M Morimoto; T Tamaoki
Journal:  J Antibiot (Tokyo)       Date:  1989-04       Impact factor: 2.649

View more
  5 in total

1.  A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.

Authors:  Tianhong Li; Scott D Christensen; Paul H Frankel; Kim A Margolin; Sanjiv S Agarwala; Thehang Luu; Philip C Mack; Primo N Lara; David R Gandara
Journal:  Invest New Drugs       Date:  2010-10-22       Impact factor: 3.850

2.  UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.

Authors:  S Abe; T Kubota; Y Otani; T Furukawa; M Watanabe; K Kumai; T Akiyama; S Akinaga; M Kitajima
Journal:  Jpn J Cancer Res       Date:  2001-05

3.  UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.

Authors:  Guoyi Wu; Nan Lin; Linan Xu; Bo Liu; Mark A Feitelson
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

4.  A High Throughput Assay for Screening Host Restriction Factors and Antivirals Targeting Influenza A Virus.

Authors:  Lingyan Wang; Wenjun Li; Shitao Li
Journal:  Front Microbiol       Date:  2016-06-03       Impact factor: 5.640

5.  Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.

Authors:  Benjamin B Mull; J Andrew Livingston; Nalini Patel; Tuyen Bui; Kelly K Hunt; Khandan Keyomarsi
Journal:  Br J Cancer       Date:  2020-01-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.